A5038511140- Renal Transplantation Outcomes and Treatments
- Organ Transplantation Techniques and Outcomes
- Neurological Complications and Syndromes
- Renal Diseases and Glomerulopathies
- Pneumocystis jirovecii pneumonia detection and treatment
- Cytomegalovirus and herpesvirus research
- Organ Donation and Transplantation
- Reproductive System and Pregnancy
- Liver Disease and Transplantation
- Immune Cell Function and Interaction
- Pharmacological Effects and Toxicity Studies
- Polyomavirus and related diseases
- HIV/AIDS drug development and treatment
- T-cell and B-cell Immunology
- Pregnancy and Medication Impact
- Transplantation: Methods and Outcomes
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Renal and Vascular Pathologies
- Organ and Tissue Transplantation Research
- Dialysis and Renal Disease Management
- Chronic Kidney Disease and Diabetes
- Diabetes and associated disorders
- Endometriosis Research and Treatment
- Mesenchymal stem cell research
- RNA Interference and Gene Delivery
Inserm
2015-2025
Université Paris-Saclay
2011-2025
Assistance Publique – Hôpitaux de Paris
2013-2025
Institut Gustave Roussy
2021-2025
Hôpitaux Universitaires Henri-Mondor
2020-2024
Bicêtre Hospital
2014-2023
Laboratoire d’immunologie intégrative du cancer
2022-2023
Fédération Hospitalo-Universitaire, Paris Center for Microbiome Medicine
2023
Université Paris-Est Créteil
2021-2022
Immunologie intégrative des tumeurs et immunothérapie du cancer
2022
Renal transplantation is the standard of care for patients with end-stage renal disease. Although maintenance immunosuppression calcineurin inhibitors yields excellent one-year survival, it associated over long term high rates death and graft loss, owing in part to adverse renal, cardiovascular, metabolic effects these agents. The use potentially less toxic agents, such as belatacept, a selective blocker T-cell activation, may improve outcomes.
Recipients of extended criteria donor (ECD) kidneys are at increased risk for graft dysfunction/loss, and may benefit from immunosuppression that avoids calcineurin inhibitor (CNI) nephrotoxicity. Belatacept, a selective costimulation blocker, preserve renal function improve long-term outcomes versus CNIs. BENEFIT-EXT (Belatacept Evaluation Nephroprotection Efficacy as First-line Immunosuppression Trial-EXTended donors) is 3-year, Phase III study assessed more (MI) or less intensive (LI)...
Recipients of extended-criteria donor (ECD) kidneys have poorer long-term outcomes compared to standard-criteria kidney recipients. We report 3-year from a randomized, phase III study in recipients de novo ECD (n = 543) assigned (1:1:1) either more intensive (MI) or less (LI) belatacept regimen, cyclosporine. Three hundred twenty-three patients completed treatment by year 3. Patient survival with functioning graft was comparable between groups (80% MI, 82% LI, 80% cyclosporine). Mean...
Notwithstanding the ongoing coronavirus disease-2019 (Covid-19) pandemic, information on its clinical presentation and prognosis in recipients of a kidney transplant remain scanty. The aim this registry-based observational study was to explore characteristics outcomes transplants included French nationwide Registry Solid Organ Transplant Recipients with Covid-19. Covid-19 diagnosed symptomatic patients who had positive PCR assay for SARS-CoV-2 or having typical lung lesions imaging. Clinical...
There are no studies which have compared the risk of severe COVID-19 and related mortality between transplant recipients nontransplant patients. We enrolled two groups patients hospitalized for COVID-19, that is, kidney (KTR) from French Registry Solid Organ Transplant (n = 306) a single-center cohort 795). An analysis was performed among subgroups matched age factors or mortality. Severe defined as admission (or transfer) to an intensive care unit, need mechanical ventilation, death. were...
Abstract In kidney transplantation, day-zero biopsies are used to assess organ quality and discriminate between donor-inherited lesions those acquired post-transplantation. However, many centers do not perform such since they invasive, costly may delay the transplant procedure. We aim generate a non-invasive virtual biopsy system using routinely collected donor parameters. Using 14,032 from 17 international centers, we develop system. 11 basic parameters predict four Banff lesions:...
ABSTRACT Recent reports have suggested a role for microtubules in the endocytic process and pointed out actin filaments early steps of apical endocytosis polarized epithelial cells. However, these studies do not address respective contribution two types along pathway. In addition, several failed to demonstrate clathrin dependent non present study we investigated both ligands internalized via coated pits (transferrin α2-macroglobulin) mouse hepatoma cell line. By immunocytochemical analysis...
Cystatin C (CST3), a strong inhibitor of cysteine proteinases, is freely filtered by the kidney glomerulus and reabsorbed tubules, where it almost totally catabolized, with remainder then eliminated in urine. In tubular diseases, seems sensible to postulate that CST3 degradation would be reduced consequently an increase its urinary elimination observed.We report here development automatic quantitative assay measure concentrations urine using Behring N-Latex kit on BNII laser nephelometer. We...
Belatacept is a first-in-class co-stimulation blocker in development for primary maintenance immunosuppression. A Phase II study comparing belatacept with cyclosporine (CsA) prevention of acute rejection and protection renal function kidney transplant recipients demonstrated similar efficacy significantly higher measured GFR at 1 year belatacept, but the incidence posttransplantation lymphoproliferative disorder was higher. Here, we present results extension this trial, which aimed to assess...
Abstract Background Little is known about the most severe forms of Pneumocystis jiroveci pneumonia (PCP) in HIV-negative as compared with HIV-positive patients. Improved knowledge differential characteristics and management modalities could guide treatment based on HIV status. Methods We retrospectively 72 patients (73 cases, 46 HIV-positive) admitted for PCP from 1993 to 2006 intensive care unit (ICU) a university hospital. Results The yearly incidence ICU admissions increased (0%) (6.5%)....
Cardiovascular disease, the most common cause of death with a functioning graft among kidney transplant recipients, can be exacerbated by immunosuppressive drugs, particularly calcineurin inhibitors. Belatacept, selective co-stimulation blocker, may provide better cardiovascular/metabolic risk profile than current immunosuppressants.Cardiovascular and metabolic endpoints from two Phase III studies (BENEFIT BENEFIT-EXT) belatacept-based regimens in recipients were assessed at month 12. Each...
Abstract The soluble HLA-G5 isoform encoded by intron-4 retaining spliced transcript has been previously detected in vivo sera and grafts from transplanted patients who had significantly better graft acceptance. These findings led us to investigate the role of tolerance induction vitro its biological relevance allograft acceptance vivo. We demonstrated that engagement Ig-like transcript-2 transcript-4 receptors is involved inhibition T cell alloproliferative responses. Naive cells sensitized...
In the Belatacept Evaluation of Nephroprotection and Efficacy as First-Line Immunosuppression Trial–Extended Criteria Donors (BENEFIT-EXT), extended criteria donor kidney recipients were randomized to receive belatacept-based (more intense [MI] or less [LI]) cyclosporine-based immunosuppression. prior analyses, belatacept was associated with significantly better renal function compared cyclosporine. this prospective analysis intent-to-treat population, efficacy safety across regimens at 7...
Post-transplantation lymphoproliferative disorder (PTLD) is associated with significant mortality in kidney transplant recipients. We conducted a prospective survey of the occurrence PTLD French nationwide population adult recipients over 10 years.A registry was established to cover and prospectively enroll all who developed between January 1, 1998, December 31, 2007. Five hundred patient cases were referred registry. The prognostic factors for investigated using Kaplan-Meier Cox...
Belatacept is a B7-specific fusion protein used to prevent allograft rejection by blocking T cell costimulation. Generally efficacious, it fails acute in sizable minority of patients. In experimental models, memory cells mediate costimulation blockade–resistant (CoBRR), but this remains undefined humans. To explore relationships between individual patients' immune phenotypes and CoBRR, we studied patients receiving belatacept or conventional calcineurin inhibitor–based immunosuppression. We...
The aim of this study (ClinicalTrials.gov, NCT01744470) was to determine the efficacy and safety two different doses extended-release tacrolimus (TacER) in kidney transplant recipients (KTRs) between 4 12 mo after transplantation. Stable steroid-free KTRs were randomized (1:1) mo: Group A had a 50% reduction TacER dose with targeted trough level (C0) >3 μg/L; group B no change (TacER C0 7–12 μg/L). primary outcome estimated GFR at 1 year. Of 300 patients, intent-to-treat analysis included...
Mesenchymal stem cells (MSCs) are powerful immunomodulators that regulate the diverse functions of immune involved in allogeneic reactions, such as T and natural killer (NK) cells, through cell-cell contact or secreted factors. Exosomes by MSCs may be their regulatory functions, providing new therapeutic tools. Here, we showed fetal liver (FL) MSC-derived exosomes inhibit proliferation, activation, cytotoxicity NK cells. bearing latency associated peptide (LAP), TGFβ, thrombospondin 1...
Vitamin D sufficiency is associated with a reduced risk of fractures, diabetes mellitus, cardiovascular events, and cancers, which are frequent complications after renal transplantation. The VITALE (VITamin supplementation in renAL transplant recipients) study multicenter double-blind randomized trial, including nondiabetic adult recipients serum 25-hydroxy vitamin (25(OH) D) levels <30 ng/mL, 12 to 48 months transplantation receive high (100 000 IU) or low doses (12 cholecalciferol every 2...
Abstract Objective To compare the performance of a newly developed race-free kidney recipient specific glomerular filtration rate (GFR) equation with three current main equations for measuring GFR in transplant recipients. Design Development and validation study Setting 17 cohorts Europe, United States, Australia (14 centres, clinical trials). Participants 15 489 adults (3622 development cohort (Necker, Saint Louis, Toulouse hospitals, France), 11 867 multiple external cohorts) who received...